TESARO Inc (TSRO) : Parametrica Management Ltd reduced its stake in TESARO Inc by 82.64% during the most recent quarter end. The investment management company now holds a total of 2,429 shares of TESARO Inc which is valued at $282,128 after selling 11,559 shares in TESARO Inc , the firm said in a disclosure report filed with the SEC on Oct 13, 2016.TESARO Inc makes up approximately 0.80% of Parametrica Management Ltd’s portfolio.
Other Hedge Funds, Including , Msi Financial Services Inc added TSRO to its portfolio by purchasing 100 company shares during the most recent quarter which is valued at $11,615. Fox Run Management L.l.c. added TSRO to its portfolio by purchasing 3,800 company shares during the most recent quarter which is valued at $438,254. TESARO Inc makes up approx 0.26% of Fox Run Management L.l.c.’s portfolio. Cupps Capital Management added TSRO to its portfolio by purchasing 17,209 company shares during the most recent quarter which is valued at $2,029,113. TESARO Inc makes up approx 0.88% of Cupps Capital Management’s portfolio. Simplex Trading added TSRO to its portfolio by purchasing 9,616 company shares during the most recent quarter which is valued at $954,484. TESARO Inc makes up approx 0.12% of Simplex Trading’s portfolio.
TESARO Inc closed down -2.58 points or -2.19% at $115.33 with 16,96,762 shares getting traded on Tuesday. Post opening the session at $117.61, the shares hit an intraday low of $114.695 and an intraday high of $118.35 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.
On the company’s financial health, TESARO Inc reported $-1.28 EPS for the quarter, beating the analyst consensus estimate by $ 0.42 according to the earnings call on Aug 4, 2016. Analyst had a consensus of $-1.70. The company had revenue of $36.60 million for the quarter, compared to analysts expectations of $2.48 million. During the same quarter in the previous year, the company posted $-1.51 EPS.
Many Wall Street Analysts have commented on TESARO Inc. Company shares were Reiterated by RBC Capital Mkts on Oct 10, 2016 to “Outperform”, Firm has raised the Price Target to $ 128 from a previous price target of $122 .Company shares were Reiterated by Wedbush on Oct 10, 2016 to “Outperform”, Firm has raised the Price Target to $ 139 from a previous price target of $107 .TESARO Inc was Upgraded by BofA/Merrill to ” Buy” on Oct 10, 2016.
TESARO Inc. (TESARO) is oncology-focused biopharmaceutical company. The Company acquires in-licenses and develops oncology product candidates. The Company has in-licensed and are developing three clinical-stage product candidates rolapitant niraparib and TSR-011. Rolapitant is a potent and long-acting neurokinin-1 or NK-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting (CINV); Niraparib formerly known as MK-4827 is an orally active and potent poly (ADP-ribose) polymerase and TSR-011 is an orally available targeted anti-cancer agent which is a potent inhibitor of both anaplastic lymphoma kinase (ALK) and tropomyosin-related kinase (TRK). The Company is also developing immuno-oncology programs by entering into a collaboration and exclusive license agreement with AnaptysBio Inc. for the discovery and development of antibodies for several specified immuno-oncology targets.